decylhydrazine | 81992-75-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: decylhydrazine
• 英文别名: Decylhydrazin
• CAS: 81992-75-8
• 化学式: C₁₀H₂₄N₂
• 分子量: 172.314
• InChiKey: QQEWMMRFXYVLQU-UHFFFAOYSA-N

物化性质

• 沸点：
  272.0±9.0 °C(Predicted)
• 密度：
  0.836±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  12
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  sodium;(Z)-1-ethoxy-1,4-dioxopent-2-en-2-olate 、 decylhydrazine 以 水 为溶剂， 反应 1.0h， 以60.3%的产率得到1-Decyl-5-methyl-1H-pyrazole-3-carboxylic acid
  参考文献：
  名称：

  降血脂药的研究。二。烷基吡唑衍生物的合成和药理性质。

  摘要：

  合成了一系列的5-烷基吡唑衍生物，并对其在大鼠中的有效降血脂活性进行了评估。发现许多在吡唑环的5位具有烷基的吡唑衍生物具有高降血脂活性。烷基链的同源性导致活性显着增加，但是在吡唑环上其他位点引入其他取代基未能增强活性。另外，用异恶唑环取代吡唑环导致活性显着降低。在测试的化合物中，5-n-十三烷基吡唑-3-羧酸（5k）表现出最有利的活性谱，并且与氯贝特一样有效。该化合物5k在急性试验（LD50 = 10.0g / kg）中显示出相当低的毒性，因此目前正在接受进一步的药理评估。

  DOI：

  10.1248/cpb.32.1568
• 作为产物：
  描述：

  癸醛 在 一水合肼 、 甲醇 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以92%的产率得到decylhydrazine
  参考文献：
  名称：

  从具有基因编码非天然药效团的噬菌体展示大环文库中进行基于基因编码片段的发现

  摘要：

  具有非天然药效团的基因编码大环肽文库是发现许多感兴趣靶点的配体的宝贵来源。传统上，此类文库的生成采用“早期”将非天然结构单元掺入化学或翻译产生的大环化合物中。在这里，我们描述了从现成的起始材料开始的此类文库的不同后期方法：基因编码的肽文库。二酮关键 1,5-二氯戊烷-2,4-二酮可将噬菌体上展示的肽库转化为带有 1,3-二酮的大环肽 (DKMP)：用于克诺尔吡唑合成的耐贮存前体。将多种肼衍生物连接到携带沉默DNA条形码的噬菌体上展示的DKMP文库上，产生大环文库，其中氨基酸序列和药效团由DNA编码。该文库针对碳酸酐酶富集的具有苯磺酰胺药效基团和纳摩尔K d 的大环化合物进行选择。本手稿中描述的方法可以将不同的药效团移植到许多现有的基因编码噬菌体库中，并显着增加此类库在分子发现中的价值。

  DOI：

  10.1021/jacs.1c01186

文献信息

• Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same
  申请人：——

  公开号：US20040242410A1

  公开（公告）日：2004-12-02

  The present invention relates to a transition metal complex represented by the formula (I): 1 wherein M represents a Group 4 transition metal; —Y— represents (a): —C(R 1 )(R 20 )-A-, (b): —C(R 1 )(R 20 )-A 1 (R 30 )—, (c): —C(R 1 )=A 1 -, or (d): —C(R 1 )=A 1 -A 2 -R 30 ; A represents a Group 16 element and A 1 and A 2 each represents a Group 15 element; R 1 to R 9 , R 20 , and R 30 are the same or different and each represents an optionally substituted hydrocarbon group, etc.; and X 1 and X 2 are the same or different and each represents a hydrogen atom, a halogen atom, an optionally substituted C 1-10 alkyl group, etc., and an intermediate product thereof, and a catalyst for olefin polymerization which comprises said transition metal complex as a component.

  本发明涉及一种由式(I)表示的过渡金属配合物：1其中M代表4族过渡金属；—Y—表示(a)：—C(R1)(R20)-A-，(b)：—C(R1)(R20)-A1(R30)—，(c)：—C(R1)=A1-，或(d)：—C(R1)=A1-A2-R30；A代表16族元素，A1和A2分别代表15族元素；R1至R9、R20和R30相同或不同，每个代表可选取代的碳氢基团等；X1和X2相同或不同，每个代表氢原子、卤原子、可选取代的C1-10烷基团等，以及其中间产物，以及包括所述过渡金属配合物作为组分的烯烃聚合催化剂。
• Azetidine ring compounds and drugs comprising the same
  申请人：Habashita Hiromu

  公开号：US20070135402A1

  公开（公告）日：2007-06-14

  It is intended to provide compounds having EDG-5 antagonism. Because of having EDG-5 antagonism, compounds of the formula (I): wherein each symbol is as defined in the description; salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof are useful as preventive and/or therapeutic agent for EDG-5 mediated diseases, for example, diseases caused by blood vessel contraction (e.g. cerebrovascular spasms disease, cardiovascular spasms diseases, coronary artery spasms disease, hypertension, pulmonary hypertension, renal diseases, myocardial infarction, angina pectoris, arrhythmia, portal hypertension, varicosity and the like), arteriosclerosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, respiratory diseases (e.g. bronchial asthma, chronic obstructive pulmonary diseases and the like), nephropathy, diabetes, hyperlipemia and the like.

  本发明旨在提供具有EDG-5拮抗作用的化合物。由于具有EDG-5拮抗作用，式（I）中的化合物：其中每个符号如描述中所定义的，其盐，N-氧化物，溶剂化物或其前药，可用作预防和/或治疗EDG-5介导的疾病的药物，例如血管收缩引起的疾病（例如脑血管痉挛疾病，心血管痉挛疾病，冠状动脉痉挛疾病，高血压，肺动脉高压，肾脏疾病，心肌梗死，心绞痛，心律失常，门脉高压，静脉曲张等），动脉硬化，肺纤维化，肝纤维化，肾脏疾病（例如肾病，糖尿病，高脂血症等）和其他疾病。
• Nitrogen-containing heterocyclic compounds and medicinal use thereof
  申请人：Habashita Hiromu

  公开号：US20070167459A1

  公开（公告）日：2007-07-19

  The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)

  式(I)和(II)所代表的化合物、其盐、N-氧化物或溶剂合物、或其前药，以及包含它们的制药组合物具有CXCR4调节作用，它们对各种炎症性疾病、各种过敏性疾病、艾滋病毒感染、或再生治疗剂具有治疗和预防作用。(其中环A代表可能具有取代基的含氮杂环基团；环B代表可能具有取代基的同环基团或可能具有取代基的杂环基团；Y代表可能具有取代基的碳氢基团、可能具有取代基的杂环基团、可能被保护的氨基、可能被保护的羟基或可能被保护的巯基；T代表环A或可能被保护的氨基。)
• TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME
  申请人：HANAOKA Hidenori

  公开号：US20100048933A1

  公开（公告）日：2010-02-25

  The present invention relates to a transition metal complex represented by the formula (I): wherein M represents a Group 4 transition metal; —Y— represents (a): —C(R 1 )(R 20 )-A-, (b): —C(R 1 )(R 20 )-A 1 (R 30 )—, (c): —C(R 1 )=A 1 -, or (d): —C(R 1 )=A 1 -A 2 -R 30 ; A represents a Group 16 element and A 1 and A 2 each represents a Group 15 element; R 1 to R 9 , R 20 , and R 30 are the same or different and each represents an optionally substituted hydrocarbon group, etc.; and X 1 and X 2 are the same or different and each represents a hydrogen atom, a halogen atom, an optionally substituted C 1-10 alkyl group, etc., and an intermediate product thereof, and a catalyst for olefin polymerization which comprises said transition metal complex as a component.

  本发明涉及一种由式(I)表示的过渡金属配合物：其中M代表4族过渡金属；-Y-代表(a)：-C(R1)(R20)-A-，(b)：-C(R1)(R20)-A1(R30)-，(c)：-C(R1)=A1-，或(d)：-C(R1)=A1-A2-R30；A代表16族元素，A1和A2各代表15族元素；R1至R9、R20和R30相同或不同，每个代表一个可选取代的碳氢基团等；X1和X2相同或不同，每个代表氢原子、卤原子、可选取代的C1-10烷基团等；以及其中间体产品和以该过渡金属配合物为组分的烯烃聚合催化剂。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF
  申请人：HABASHITA Hiromu

  公开号：US20120156219A1

  公开（公告）日：2012-06-21

  The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)

  化合物(I)和(II)的化学式、其盐、N-氧化物或其溶剂化物，或其前药以及包含它们的制药组合物具有CXCR4调节作用，对各种炎症性疾病、各种过敏性疾病、人类免疫缺陷病毒感染的获得性免疫缺陷综合症，或再生治疗剂具有治疗和预防作用。(其中环A代表一个含氮杂环基团，可以有取代基；环B代表一个同环基团，可以有取代基或一个含氮杂环基团，可以有取代基；Y代表一个碳氢基团，可以有取代基，一个含氮杂环基团，可以有取代基，一个氨基可以被保护，一个羟基可以被保护或一个巯基可以被保护；T代表环A或一个氨基可以被保护。)